PubMed Health⌕ Search

Biomedical subjects

E Escher

Publications and source records attributed to E Escher.

At least 109 records · Page 6Linked to original sources
PubMed1984

Angiotensin-induced changes in the apparent size of rat liver angiotensin receptors.

Angiotensin receptors from rat liver were labeled using four different ligands: (Sar1-(3H)Tyr4)-Angiotensin ll ((3H)SarAll); (Sar1-(3H)Tyr4-lle8)-Angiotensin ll ((3H)SarlleAll); (Sar1-(125I) Tyr4-(4'-N3) Phe8)-Angiotensin ll (IN3All); (Sar1-(125I)Tyr4-(4'N3D-Phe)8)-Angiotensin ll (IN3DPheAll). (3H)SarAll and IN3All behaved like agonists and (3H)SarlleAll and IN3DPheAll like antagonists. All four ligands labeled the same population of sites. The azido derivatives allowed covalent labeling of receptors with a high yield (about 40%). Membranes were solubilized by Triton X-100 under experimental conditions which ensured complete solubilization of the liganded receptors in a stable form (less than 40% dissociation after 20 h). The apparent size of liganded angiotensin receptors was determined by gel filtration on Ultrogel ACA-34 columns and by SDS gel electrophoresis (in the case of covalent labeling). The apparent Stokes radius of solubilized angiotensin receptors was different wether the receptor was labeled with an agonist (Stokes radius = 6.2 +/- 0.1 nm (6) after labeling with (3H)SarAll) or with an antagonist (Stokes radii of 5.5 +/- 0.1 (7), and 5.6 +/- 0.1 nm (4) after labeling with (3H)SarlleAll and IN3DPheAll respectively). After covalent labeling with IN3All angiotensin receptors were eluted as a mixture of light and heavy forms. SDS gel electrophoresis revealed only one molecular entity of Mr 64,000. It is concluded that binding of an agonist to liver angiotensin receptors triggers or stabilizes an interaction with another membrane component involved in the coupling of the receptor to its primary effector.

Angiotensin II↗
PubMed1984

A new method of iodine labelling of peptide hormones.

Usually peptide hormones and related compounds are radioactively labelled with iodine on tyrosine residues of the peptide. However many peptide hormones do not contain tyrosine or the iodinated tyrosine interferes with the biological properties. In order to circumvent these and other problems, a general method is proposed which allows the introduction of iodine into the para-position of phenylalanine with a modified Sandmeyer procedure. This last-step modification together with HPLC purification permits the obtention of carrier-free and metabolically stable labelled products with maximal specific activity possible. The model has been carried out on several peptide-models like angiotensin II, endorphine and head activator peptide.

Angiotensin II↗
PubMed1983

Analysis of the adrenal angiotensin II receptor with the photoaffinity labeling method.

The angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, AT) receptor of bovine adrenocortex has been investigated with photosensitive analogues of AT. In a first series of experiments, we have shown that isolated cortical cells secrete aldosterone in a permanent and specific manner if they have been photolyzed in the presence of the photolabel [Sar1,(4'-N3)Phe8]AT. This permanent stimulation is in contrast to the smooth muscle assays where under similar conditions a permanent and specific block was always observed. It is assumed that the irreversible occupation of the AT receptor produces this effect. In a second type of experiment, we have shown that the AT binding site on adrenocortical membranes can be specifically and irreversibly occupied under similar conditions and that this occupation can be prevented in a competitive manner by the presence of nonphotosensitive hormone. Using a radioactive label, [Sar1,(3'-125I)Tyr4,(4'-N3)Phe8]AT, we have identified the AT receptor as a 300-kDa protein by means of gel filtration under nonreducing and nondenaturating conditions. Under reducing and denaturing conditions, a subunit of 60 kDs was found by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel filtration. The AT receptor is proposed to be a 300-kDa protein with one binding subunit of 60 kDa.

Adrenal Cortex↗
PubMed1982

Substance P antagonists active in vitro and in vivo.

[Pro4, Trp7,9]SP-(4-11) and a newly developed compound, [Pro4, Trp7,9,10]SP-(4-11) were shown to be potent antagonists of substance P (SP). They inhibited the hypotensive effect of SP in the anesthetised rats, the vasodilator effect in the rabbit perfused heart and the relaxation induced by SP in dog carotid arteries contracted with noradrenaline. Stimulatory actions of SP in the guinea pig ileum and the guinea pig trachea were also inhibited by the two antagonists, which were shown to be specific for substance P and related peptides in all the pharmacological preparations utilised in the present study.

Animals↗
PubMed1982

Synthesis and biological activities of photoaffinity labeling analogues of substance P.

Substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-MetNH2, SP) is an undecapeptide with important properties as a neurotransmitter and with other functions. No specific antagonists and no long-acting analogues of this peptide hormone are known to date. In order to reach these goals, analogues of SP have been prepared which contain potential affinity, as well as photoaffinity labeling functions, suitable for irreversible attachment to SP receptors. We report here the synthesis of SP analogues which have the Phe residues in positions 7 or 8 replaced with (4'-NO2)Phe, (4'-NH2)Phe, (4'-N2+)Phe, and (4'-N3)Phe. Some of these peptides are used for photoaffinity labeling studies using various bioassays. The synthesis of the (NO2)Phe-containing peptide was carried out on solid phase using Nle instead of Met and the Boc strategy up to residue 4; the remaining amino acids were added using an Fmoc strategy. The protected undecapetide was cleaved by ammonolysis, purified by chromatography on silica gel with chloroform/methanol and deprotected afterwards. The amino, diazonium, and azido peptides were obtained in this sequence by chemical modification of the nitro peptides. On guinea pig ileum the modified peptides in position 8 had close to maximal activity, whereas modifications in position 7 produced some reduced activity, especially the nitro modification. No diazonium peptide produced any irreversible effects on guinea pig ileum. Photoinactivation studies were carried out on strips of guniea pig trachea, but no irreversible effects have been observed, neither permanent stimulation nor permanent inactivation. The biological activities and effects are discussed in view of the molecular properties of the synthesized analogues.

Affinity Labels↗
PubMed1982

Synthesis and biological activities of substance P antagonists.

Several substance P analogues containing various D-amino acid modifications have been synthesized by the solid-phase procedure, detached from the solid support by ammonolysis, and purified by gel filtration combined with reversed-phase chromatography. Three compounds were fair to very potent competitive antagonists of substance P on three bioassays, i.e., guinea pig ileum, rabbit mesenteric vein, and guinea pig trachea. [Arg6,D-Trp10]SP(6-11) is a reasonable antagonist in all three bioassays and [D-Pro4,D-Trp7,9]SP(4-11) is a very potent competitive antagonist with pA2 values ranging around 6.0.

Animals↗
PubMed1982

Structure-activity studies on the C-terminal amide of substance P.

Twelve C-terminal heptapeptide analogues of substance P have been synthesized by solid phase and by the classical solution method. The modifications concerned all the C-terminal primary amide of SP and should therefore help to understand the biological significance of this carboxamide, as evaluated by in vivo and in vitro bioassays. From the results it can be seen that not the slightest change of the two amide protons is tolerated without an important loss of activity: replacement of one or two amide protons with alkyl groups, extension of the amide to the hydrazide and its alkyl analogues, and exchange of the amide with an ester or a carboxylic acid all reduce the relative activity/affinity at least by 2-fold. It is not clear for what reason all these modifications produce such a drastic activity reduction.

Animals↗
PubMed1981

Studies on position 1 of angiotensin II: effects on affinity and duration of action from alkyl amide substitution.

The synthesis and the biological activities of [asparagine]angiotensin II analogues with alkyl-substituted amide groups are reported. This study was performed in order to elucidate further the importance and the influence of the side chain in position 1 of angiotensin II. The two synthesized analogues [1-(N4,N4-dipropyl)asparagine]- and [1-(N4,N4-diisopropyl)asparagine]angiotensin II were compared to [1-asparagine]angiotensin II (hypertensin, Ciba) and to [1-(N4,N4-dimethyl)asparagine]angiotensin II in vitro and in vivo. All compounds had full intrinsic activity, but their potency decreased with increasing alkyl size of the substituted carboxamide group. Despite their reduced potency, the alkylated analogues showed enhanced duration of action on rabbit aorta strips. The relative potencies of the series hypertensin, dimethyl, dipropyl, and diisopropyl analogues on rabbit aorta strips were 100, 46, 16, and 9%, respectively. In the rat blood pressure assay they were 100, 30, 9, and 7%, respectively.

Alkylation↗
PubMed1981

Biological activities of photoaffinity labeling analogues of kinins and their irreversible effects on kinin receptors.

Several analogues of bradykinin and [des-Arg9]bradykinin with potentially reactive groups have been tested for their biological activities. In these analogues, phenylalanine was replaced by the aromatic amino acid (4'-nitro)Phe, (4'-amino)Phe, (4'-azido)Phe, and (4'-diazonium)Phe, as well as with other residues. [Des-Arg9]bradykinin and the octapeptide analogues were tested on rabbit aorta strips, an assay organ containing the B1 receptor which is activated by the octapeptide [des-Arg9]bradykinin. Strips of rabbit jugular vein served as bioassays for bradykinin and the nonapeptide analogues, because the rabbit jugular vein bears the receptor B2 which is sensitive to bradykinin nonapeptides. The biological findings support the interpretation that kinins act on two different receptor types, since the potency orders of the analogues in the two bioassays are different. All potential photolabels retained reasonable affinities in the dark, except [(4'-azido)Phe8,des-Arg9]bradykinin, which, however, proved to be a weak and competitive antagonist of [des-Arg9]bradykinin on the rabbit aorta. Inactivation experiments with the unstable (4'-diazonium)Phe-containing peptides did not show any irreversible effect in the two bioassays. Photoaffinity labeling experiments with the azido and the nitro peptides gave irreversible and specific effects on both the rabbit aorta and the jugular vein. [(4'-Azido)Phe8,des-Arg9]bradykinin photolyzed at 365 nm on the rabbit aorta reduced the sensitivity of this tissue against [des-Arg9]bradykinin specifically to about one-third of its initial value. [(4'-Azido)Phe5]bradykinin reduced the sensitivity of the rabbit jugular vein to bradykinin by more than 50%. The observed irreversible effects were always loss of myotropic activity and never permanent contraction.

Affinity Labels↗
PubMed1980

Pharmacological properties of two analogues of angiotensin II containing carboranylalanine (Car).

The pharmacological properties of two angiotensin II analogues containing carboranylalanine (Car) are reported. Sar-Arg-Val-Tyr-Val-His-Pro-Car is a weak partial agonist showing 15% intrinsic activity and a very long lasting action, specific for the angiotensin II receptor of the rabbit aorta. Sar-Arg-Val-Car-Val-His-Pro-Phe is inactive on the angiotensin II receptor. These properties are discussed in view of recent findings on the action of angiotensin II on its smooth muscle receptor.

Angiotensin II↗
PubMed1979

Study on the influence of tyrosine deprotonation on the myotropic action of angiotensin II.

The influence of phenolic tyrosine ionization in angiotensin II on the myotropic action of this peptide has been investigated in vitro on rabbit aortic strips. [Sar1, Tyr4]angiotensin II and [Sar1, (4'-amino) Phe4]angiotensin II (as a reference which cannot undergo the same ionization) were tested over a pH range from 6.8 to 9.0 and their activities compared. The results clearly indicate that angiotensin II with a deprotonated phenolic hydroxyl group on Tyr in position 4 is not the most active or only active form of angiotensin II.

Angiotensin II↗
PubMed1978

Photoaffinity labeling of the angiotensin II receptor; pharmacology of the labeling peptides in the dark.

The biological activities of photoaffinity labeling analogs of angiotensin II (ATII) and their precursors were measured in rabbit aorta strips in the dark. Most of the analogs behave as reversible, specific agonists, one as a competitive inhibitor. The activities are discussed in line with the current view of structural requirements. The modifications consisted of substitutions on the aromatic nuclei of Tyr4 and Phe8 in [Sar1]ATII with (4'-NO2) Phe, (4'-NH2)Phe, (4'N3)Phe, (4'-N2 +)Phe, and (4'-NH2-3', 5'-I2)Phe. It is shown that the affinity of the ATII analogs modified in position 4 depends on the electronegativity and not on space-filling properties of the aromatic residue; rising electronegativity lowers the affinity, i.e. [sar1, (4'-NO2)Phe4]ATII has no more measurable activity. Substituting the aromatic side chain in position 8 of [Sar1]ATII gives well-binding analogs with intrinsic activities from 0 to 100% and activity seems to depend only on stereochemical requirements. Agonists and partial agonists bear rather small groups like -NH2, -N3, -NO2, and -N2 +. The only antagonist [Sar1, (4'-NH2-3',5'-I2)Phe8]ATII resembles the antagonist E1Sar1, Leu8]ATII in competitivity and binding.

Angiotensin II↗